科研之友
微信
新浪微博
Facebook
分享链接
摘要
Despite routine treatment of unselected acute promyelocytic leukemia (APL) with all-transretinoic acid (ATRA), earlydeathbecauseofhemorrhageremainsunacceptably common, and themechanismunderlyingthiscomplicationremainselusive. Wehaverecentlydemonstrated that APL cells undergo a novel cell death program, termed ETosis, which involves release of extracellular chromatin. However, the role of promyelocytic extracellular chromatin in APL-associated coagulation remains unclear. Our objectives were to identify the novel role of ATRA-promoted extracellular chromatin in inducing a hypercoagulable and hyperfibrinolytic state inAPL and to evaluate its interactionwith fibrin and endothelial cells (ECs). Results from a series of coagulation assays have shown that promyelocytic extracellular chromatin increases thrombin and plasmin generation, causes a shortening of plasma clotting time of APL cells, and increases fibrin formation. DNase I but not anti-tissue factor antibody could inhibit these effects. Immunofluorescence staining showed that promyelocytic extracellular chromatin and phosphatidylserine on APL cells provide platforms for fibrin deposition and render clots more resistant to fibrinolysis. Additionally, coincubation assays revealed that promyelocytic extracellular chromatin is cytotoxic to ECs, converting them to a procoagulant phenotype. This cytotoxity was blocked by DNaseIby20% or activatedproteinCby31%. Our current results thusdelineate thepathogenic role ofpromyelocytic extracellular chromatin in APL coagulopathy. Furthermore, the remaining coagulation disturbance in high-risk APL patients after ATRA administration may be treatable by intrinsic pathway inhibition via accelerating extracellular chromatin degradation.
- 出版日期2017-3-30
- 单位哈尔滨医科大学
